Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Therapeutic Modalities

Targeting oxMIF To Develop Novel Biotherapeutics

An interview with Michael Thiele, Chief Scientific Officer, OncoOne Research & Development GmbH.
Read More
Therapeutic Modalities

Chipscreen Licences Eucure Biopharma's Keytruda Competitor for Greater China

The investigational bispecific antibody has demonstrated favourable efficacy and safety in preclinical in vivo testing.
Read More
Therapeutic Modalities

Therapy In the Spotlight: CAR T Cell Therapy—Significant Approvals and Regulatory Concerns

What are the regulatory considerations for CAR T cell therapy, and what's next for the approach?
Read More
Therapeutic Modalities

Novel TNF Superfamily Antagonists for Cancer & Autoimmunity

An interview with Russell LaMontagne, Co-Founder and Chief Executive Officer, Boston Immune Technologies and Therapeutics
Read More
Therapeutic Modalities

Antibody Discovery by Single B Cell Screening on Beacon®

On-Demand Webinar featuring Dr Amy Sheng, Technical Account Manager at Sino Biological
Read More
Therapeutic Modalities

Experts Discuss Developing Oncolytic Virus Immunotherapy

Our November Immuno-Oncology Discussion Group brought together experts in the field of oncolytic virus development to discuss engineering and translational strategies of the field
Read More
Therapeutic Modalities

What are the Key Challenges in Developing Bispecific Antibodies for Cancer Immunotherapy?

Are there too many opportunities in antibody-based immunotherapy? How do you choose your targets? How do you know when to kill a project?
Read More
Therapeutic Modalities

Viral Immunotherapy: A New Approach Towards Tackling Solid Tumours

As an alternative avenue for addressing difficult-to-treat cancers, viral immunotherapies hold significant promise. CAN-2409 is well-tolerated in phase II clinical trials in patients with prostate cancer, and new applications may be on the horizon.
Read More
Therapeutic Modalities

T Cell Enhancers: Conditional Activation for a Safe and Durable Response

Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses.
Read More
Therapeutic Modalities

Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape

Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics.
Read More
Therapeutic Modalities

Biologics Solutions: Plasmid DNA - Charles River

Read More
Therapeutic Modalities

Biologics Solutions: Viral Vectors - Charles River

Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno